Design, Synthesis, and Antitubercular Activity of Thiolutin–Cycloserine Hybrids: Reducing Cytotoxicity

Zhibin Sun, Xiaolong Chen, Shanfeng Shi, Yongqi Mu, Chuanxing Wan, Guoguo He · 2026

Read Design, Synthesis, and Antitubercular Activity of Thiolutin–Cycloserine Hybrids: Reducing Cytotoxicity by Zhibin Sun, Xiaolong Chen, Shanfeng Shi, Yongqi Mu, Chuanxing Wan, Guoguo He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13515660.txt.

Description

Sun and colleagues built new drug candidates against tuberculosis by fusing two known weapons into single molecules, work reported in 2026. One half is thiolutin, a natural antibiotic; the other half comes from medicines already used against tuberculosis, including cycloserine and isoniazid. Chemical linkers of seven to ten carbon atoms join the two halves. The hope is that a combined molecule keeps the killing power of thiolutin while softening its harm to human cells.

The team synthesized 15 hybrid molecules and tested them against the tuberculosis bacterium. Cycloserine hybrids worked best, stopping bacterial growth at concentrations as low as 1 microgram per milliliter in the reported assays. Safety tests in mouse immune cells were encouraging: every cycloserine hybrid needed more than 40 micrograms per milliliter to harm half the cells, far gentler than thiolutin alone. Two hybrids, T1-CS and T4-CS, gave the best balance of potency and safety.

Catalog record

CREATORZhibin Sun, Xiaolong Chen, Shanfeng Shi, Yongqi Mu, Chuanxing Wan, Guoguo He
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13515660

Browse the full library · About the Tower of Babel